Schizophrenia: The drug deadlock - Nature (original) (raw)

The biology is too complicated. Pharma companies are quitting. Where are schizophrenia drugs going to come from?

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Lieberman, J. A. et al. N. Engl. J. Med. 353, 1209-1223 (2005).
    Article CAS Google Scholar
  2. Buchanan, R. W. et al. Schizophr. Bull. 31, 5-19 (2005).
    Article Google Scholar
  3. Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr & Marder, S. R. Schizophr. Bull. 32, 214-219 (2006).
    Article Google Scholar
  4. Steffanson, H. et al. Nature 455, 232-236 (2008).
    Article ADS Google Scholar

Download references

Rights and permissions

About this article

Cite this article

Abbott, A. Schizophrenia: The drug deadlock.Nature 468, 158–159 (2010). https://doi.org/10.1038/468158a

Download citation

This article is cited by